Workflow
IDE034
icon
Search documents
百奥赛图合作伙伴获进展 创新双抗ADC年内申报临床
记者9月23日从百奥赛图获悉,公司授权给美国IDEAYA公司的创新肿瘤药物IDE034研发获得重要进 展,展现出对肺癌、结直肠癌等多癌种的潜在治疗潜力,IDEAYA计划今年四季度在美国提交IDE034的 临床试验申请。 IDE034不是一款普通的抗体偶联药物(ADC)新药,它能够同时识别B7H3与PTK7两个肿瘤标志物, 也就是双靶点协同机制,这意味着它能更精准地锁定肿瘤细胞,提高治疗效果和安全性。IDE034还搭 载百奥赛图专有的新型连接子与载荷平台BLD1102,能与IDEAYA的相关技术形成协同作用,发挥更强 的临床效果。这是百奥赛图与国外公司开展管线授权合作的又一进展。 此前,百奥赛图的B7H3/PTK7全人源双抗ADC管线授权给IDEAYA公司,潜在交易总额近人民币30亿 元。不到一年时间,这条管线就有了快速进展,如果推进顺利,有望成为全球首个进入临床的 B7H3/PTK7双靶点ADC药物。 IDE034由百奥赛图自主研发的RenLite全人抗体共轻链平台筛选获得,这一平台能够有效避免轻重链错 配,提高研发成功率。尤其是在双抗ADC领域,百奥赛图还开发了RenNano平台,可以产生全人纳米抗 体,可 ...
百奥赛图授权管线IDE034进展提速,或成全球首个B7H3/PTK7双靶ADC
Guan Cha Zhe Wang· 2025-09-23 08:06
9月23日,百奥赛图(02315.HK)发布消息称,公司授权给美国IDEAYA Biosciences公司的肿瘤治疗药 物IDE034项目取得阶段性进展。据介绍,该药物在肺癌、结直肠癌等癌种中显示治疗潜力,IDEAYA计 划于2024年四季度向美国监管部门提交临床试验申请。 IDE034是一款抗体偶联药物(ADC),采用双靶点设计,能够同时识别B7H3与PTK7两个肿瘤标志 物。该产品搭载百奥赛图的连接子与载荷平台BLD1102技术。 此前在2024年11月,百奥赛图将其B7H3/PTK7全人源双抗ADC项目授权给IDEAYA公司,潜在交易金额 接近30亿元人民币。若进展顺利,该项目有望成为该双靶点领域的首个临床阶段ADC产品。 IDE034基于百奥赛图的RenLite全人抗体共轻链平台开发。公司在双抗ADC领域还拥有RenNano平台, 可产生全人纳米抗体。百奥赛图依托其RenMice全人抗体小鼠平台建立了抗体分子库,为制药企业提供 研发服务。 在国际合作方面,百奥赛图在双抗ADC领域的合作伙伴包括SOTIO、ABL Bio、Radiance及ADC Therapeutics等。在抗体开发领域,公司与吉利德 ...
百奥赛图:从“抗体超市”到全球合作热单,双业务线越跑越顺
Xin Lang Zheng Quan· 2025-09-22 05:56
Core Insights - The pharmaceutical industry is currently focused on dual antibodies, ADCs, and nucleic acid delivery systems, with significant data emerging from WCLC regarding dual antibody ADCs [1] - Baiaosaitou has been actively collaborating with various partners, including Merck and Tubulis, to enhance its capabilities in antibody-drug conjugates and nucleic acid delivery [1][4][5] Group 1: Business Model and Strategy - Baiaosaitou has transformed the complex molecular discovery process into a "shelf-style" selection, allowing partners to choose from a vast library of potential drug candidates, significantly reducing time and increasing success rates [2] - The company operates with a dual business model: one focusing on model animals for target humanization and disease modeling, and the other on antibody platforms that continuously produce antibodies for licensing and joint development [3] Group 2: Recent Collaborations and Developments - The collaboration with Merck aims to enhance the delivery of nucleic acid drugs through antibody-conjugated LNPs, potentially benefiting mRNA and siRNA therapies [4] - Tubulis has selected a fully human antibody from Baiaosaitou's RenMice® platform to develop a new generation of ADCs, with Baiaosaitou receiving upfront payments, milestone payments, and sales royalties [5] - IDEAYA's IDE034, developed from the RenLite® platform, targets two tumor-related antigens and is expected to file for IND by Q4 2025, indicating a strong pipeline for dual antibody ADCs [6] Group 3: Market Position and Trends - The global pharmaceutical industry is facing a patent cliff, creating a demand for new pipelines, which aligns with Baiaosaitou's strategy of focusing on molecular discovery and validation tools rather than broad self-research [7] - The shift from single-target competition to multi-target and delivery systems positions Baiaosaitou as a key player in providing reliable molecules and validation tools, establishing itself as a foundational infrastructure in the industry [8]